Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma (ARTEMIDE-HCC01)
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Sponsor: AstraZeneca
Listed as NCT06921785, this PHASE3 trial focuses on Hepatocellular Carcinoma and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 8 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .